Skip to content

Elective Abdominal Aortic Aneurism - Open Versus Endovascular Repair

ACE Trial :Not Worn-Out Aneurism of the Abdominal Aorta Under Renal Surgery Versus Endoprosthesis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00224718
Acronym
ACE
Enrollment
306
Registered
2005-09-23
Start date
2003-01-31
Completion date
2009-02-28
Last updated
2009-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective Abdominal Aortic Aneurysm

Keywords

Abdominal aortic aneurysm, Endograft, Open repair, Endovascular repair, AAA

Brief summary

Abdominal aortic aneurysm (AAA) is a life threatening disease. There is a consensus to propose surgical repair in patients with a reasonable operative risk when the AAA exceeds 5 cm in diameter. The aim of the study is to compare the mortality and the occurrence of severe general, vascular and local complications in two groups of patients treated by either by open surgery or by EVAR (EndoVascular Aneurysm Repair). The main outcome criteria and the secondary endpoint are respectively the survival without severe complications and minor morbidity.

Detailed description

ACE Trial :Not Worn-Out Aneurism of the Abdominal Aorta Under Renal Surgery Versus Endoprosthesis Abdominal aortic aneurysm (AAA) is a life threatening disease. There is a consensus to propose surgical repair in patients with a reasonable operative risk when the AAA exceeds 5 cm in diameter. The aim of the study is to compare the mortality and the occurrence of severe general, vascular and local complications in two groups of patients treated by either by open surgery or by EVAR (EndoVascular Aneurysm Repair). The main outcome criteria and the secondary endpoint are respectively the survival without severe complications and minor morbidity.

Interventions

PROCEDUREEndovascular repair (with endograft)

An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).

PROCEDUREOpen repair

Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 50 years old or more (more than 80 possible depending on physiological age) * Level 0, 1, or 2 of operative risk * Abdominal aortic aneurysm with a diameter \> or equal to 50 mm or \> or equal to 40 mm if rapid growing (10 mm or more in a year), or painful, or saccular aneurysms, or aneurisms of common iliac arteries with a diameter equal or superior to 30 mm; or women with a diameter equal to 45 mm; * Aortic neck superior or equal to 1.5 cm * No stenosis superior or equal to 75% of the superior mesenteric artery * Proximal neck angulation inferior to 80° * Diameter of the iliac arteries compatible with introducer sheath * Inform consent signed

Exclusion criteria

* Aneurysm involving the renal arteries or with the length of the neck less than 1.5 cm * Thrombus or major calcification in the neck * Diameter of the iliac arteries not compatible with introducer sheath * Level 3 of operative risk * History of major iodine allergy (Quincke oedema, anaphylactic shock) * Other comorbidity with life expectancy less than 6 months * Follow up impossible during the trial * Participation in another trial * Inform consent not signed

Design outcomes

Primary

MeasureTime frame
Death and major adverse events4 years

Secondary

MeasureTime frame
Minor adverse events (systemic vascular or non vascular complications)4 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026